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This study was designed to test the hypothesis that fetal exposure to corticosteroids in the antenatal period is an independent risk
factor for the development of asthma in early childhood with little or no eﬀect in later childhood. A population-based cohort
study of all pregnant women who resided in Nova Scotia, Canada, and gave birth to a singleton fetus between 1989 and 1998
was undertaken. After a priori speciﬁed exclusions, 80,448 infants were available for analysis. Using linked health care utilization
records, incident asthma cases developed after 36 months of age were identiﬁed. Extended Cox proportional hazards models were
used to estimate hazard ratios while controlling for confounders. Exposure to corticosteroids during pregnancy was associated
with a risk of asthma in childhood between 3–5 years of age: adjusted hazard ratio of 1.19 (95% conﬁdence interval: 1.03, 1.39),
with no association noted after 5 years of age: adjusted hazard ratio for 5–7 years was 1.06 (95% conﬁdence interval: 0.86, 1.30)
and for 8 or greater years was 0.74 (95% conﬁdence interval: 0.54, 1.03). Antenatal steroid therapy appears to be an independent
risk factor for the development of asthma between 3 and 5 years of age.
1.Introduction
Research on the etiology and natural history of asthma
has identiﬁed a web of predisposing factors (e.g., genetics,
atopy), causal factors that may sensitize the airways (e.g.,
animal dander, dust mites, workplace allergens) and con-
tributing factors (perinatal events such as mode of delivery,
exposure to cigarette smoke during pregnancy, gestational
age and childhood respiratory infections, air quality, socioe-
conomic status, and pollution) [1–6]. Conclusions that can
be drawn from this research outline a myriad of exposures
and complex interactions in the etiology of pediatric asthma
[7–10].
Given the complex nature of pediatric asthma etiol-
ogy, factors in the perinatal period that would predispose
individuals to asthma are of particular interest [11, 12].
Corticosteroid(CS)therapy,administeredduringlabourand
delivery to accelerate fetal lung maturation, has not been
fully examined as a potential risk factor for the development
of asthma in humans [13]. CS therapy has been shown
to alter the development of the fetal lung and has been
linked, in animal studies, to changes in brain chemistry and
subsequenthypertensionlaterinlife[14–28].Complextime-
dependent relationships between CS therapy and subsequent
lung function in animals has been noted [29].
TheuseofCStherapy,inCanada,amongpreterminfants
before 34 weeks’ gestation has increased in the last 15 years
from less than 25 percent to approximately 60 percent [30,
31]. This increase of CS therapy follows from randomized
controlled trial evidence indicating increased infant survival
among preterm infants exposed to antenatal CS therapy
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A limited number of previous studies have investigated
lung function (not asthma) in childhood among those
previously exposed to CS therapy [33–36]. The small sample
sizesandconveniencesamplesofthesestudiesdonotprovide
suﬃcient evidence for or against an association between
CS therapy and asthma [13]. Therefore, a large population-
based cohort study where confounding by indication can be
controlled is warranted.
This study was designed to test the hypothesis that fetal
exposure to corticosteroids in the antenatal period is an
independent risk factor for the development of asthma in
childhood. Further, the risk of asthma is hypothesized to be
greater in the early childhood years and attenuated in later
childhood.
2. Methods
Apopulation-basedcohortstudyofallpregnantwomenwho
resided in Nova Scotia, Canada and gave birth to a singleton
fetus between January 1, 1989, and December 31, 1998, and
lived to discharge was undertaken.
Data from The Maternal-Child Health Database
(MCHD) were used. The MCHD is a longitudinal
population-based database of all mothers and infants
delivered while resident in Nova Scotia that is linked to
health services utilization data. Four independently collected
linked databases comprise the MCHD used in this study
including data fromthe Nova Scotia Atlee Perinatal Database
(NSAPD), the Nova Scotia physician visits Medical Services
Insurance File database, the Nova Scotia Vital Statistics
Database and the Nova Scotia portion of the Canadian
Institute for Health Information hospital admissions
database.
Pregnancies that resulted in the birth of more than one
infant (twins, triplets, quadruplets) diﬀer from singleton
pregnancies both physiologically and obstetrically and there-
fore were not eligible for inclusion. Mothers who suﬀer from
thyroid conditions (due to higher levels of hormones already
present) and mothers experiencing active asthma during
the gestational period (due to increased risk of obstetrical
complications andthepossibility offetalexposure tosteroids
because of the pharmaceutical interventions used to manage
the mothers asthma) were also excluded [37–39].
Previous work in Canada has established that health
service administrative records can be used to identify and
describe children with asthma [40–43]. The deﬁnition of
asthma employed in this study was based on this pre-
vious work, determined by examining physician visits or
hospitalizations where the primary diagnostic ﬁeld was for
asthma or asthma-like conditions (asthma: ICD-9-CM code
493, bronchitis: ICD-9-CM code 490, or bronchiolitis: ICD-
9-CM code 466). Subjects who experienced at least two
health care interactions in any 365 day period, starting at
156 weeks post birth (3 years), where the diagnosis was
asthma or an asthma-like condition and at least one visit
was not in the winter period (December to March inclusive),
or experienced one hospitalization speciﬁcally for asthma
(ICD-9-CM code 493) were considered to be asthmatic [40].
This deﬁnition captures all levels of asthma severity.
A second more conservative deﬁnition of asthma was
developed to examine the potential that the primary def-
inition would be too encompassing and therefore have a
high level of misclassiﬁcation. The conservative deﬁnition
of asthma was similar to the primary deﬁnition except that
only interactions where asthma (ICD-CM code 493) was the
primary diagnostic ﬁeld were considered.
The primary exposure of interest is antenatal CS therapy.
Maternal systemic steroid therapy is coded in the NSAPD
[44]. The ﬁrst dose of the ﬁrst course of betametha-
sone or dexamethasone coupled with the timing of the
administration is recorded. For this study, infants were
considered exposed to CS therapy if either of these drugs was
administered regardless of timing.
Numerous potential risk factors for childhood asthma
have been identiﬁed in the literature. Potential confounders
considered in this analysis included the infant’s sex, ges-
tational age at birth, maternal age, one minute Apgar
score, administration of surfactant, infant’s birth weight,
delivery by caesarian section, maternal smoking during
the gestational period, socio-economic status (SES), hyaline
membrane disease, bronchopulmonary dysplasia, maternal
insulin dependant diabetes mellitus, gestational diabetes,
number of siblings, and year of birth.
The infant’s gestational age at birth, in completed weeks,
was examined both continuously and as a dichotomous
variable indicating full term/preterm, with full term being
37 or more completed weeks of gestation. Infants born at
an early gestational age are at increased risk of poor lung
function and preterm labour is often used as an indication
for CS therapy [30, 45–47].
2.1. Confounding. Control for confounding by indication
was achieved in this study given not all infants who are
preterm or low birth weight were exposed to CS therapy and
aportionofinfantswhoarefull-termorfullbirthweightwill
have been exposed. There is a portion of infants in each year
of the cohort where the therapy is clinically indicated, but
for various reasons not administered (e.g., where mothers
presented to the hospital too late). Also, there is a portion
of infants in each year of the cohort where the therapy is
clinicallyindicated andadministered, butforvarious reasons
delivery was able to be delayed until the infant was delivered
full term. Therefore, each year a proportion of preterm and
low birth weight infants are unexposed and a portion of
full-term infants are exposed to CS therapy allowing for
diﬀerences in the development of childhood asthma to be
examined.
Maternal age was examined continuously. Given mater-
nal age has been shown to be related to preterm birth
and related to obstetrical complications leading to the
administration of CS, maternal age was only considered
as a confounder in this analysis [31, 48]. The infants one
minute Apgar score (examined in three categories, 0–3, 4–
6, 7–10) has been shown to be an independent risk factor
for childhood asthma [49]. Delivery by caesarean sectionJournal of Pregnancy 3
was examined as a dichotomous variable where, regardless
of other obstetrical interventions during delivery (e.g., the
use of forceps prior to surgery), if the infant was ultimately
born by caesarean section it was considered a caesarean
section.DeliverybycaesareansectionisrelatedtoCStherapy
and CS therapy has been shown to be associated with poor
lung function in the infant [49, 50]. Maternal smoking
during pregnancy was examined as a dichotomous variable.
Cigarette exposure during the gestational period has been
shown to be related to the development of childhood asthma
andriskofobstetricalcomplications(includingprematurity)
that are related to the administration of CS [47, 51–56].
Diﬀerences in the complication rate and the potential for
threatened preterm labour is increased when the mother is
diagnosed with either type 1 diabetes mellitus or gestational
diabetes.
Hyaline membrane disease is a respiratory condition in
the infant that is often associated with preterm delivery and
subsequent morbidity. CS therapy was primarily instituted
to ameliorate this disease. However, the administration of
surfactant to alleviate various respiratory diﬃculties in the
infant after birth, such as hyaline membrane disease, has
been shown to be related to both long term lung function
and the use of CS therapy [57–60].
Due to the declining incidence of asthma over the time
period under study, the year of birth was used to control for
birth cohort eﬀects (temporal eﬀects).
A greater number of older siblings in a household
has been shown to be associated with reduced risk of
childhood asthma and forms part of the basis for the
hygiene hypothesis [61–63]. Also related to the hygiene
hypothesis is the socioeconomic status of the infants family
[64, 65]. Mothers who are of low socioeconomic status are
also more likely to have various pregnancy complications
that include threatened preterm labour [66]. Therefore, two
socioeconomic status measures were used in this study.
Marital status at the time of delivery (married or common
law versus single, widowed, divorced, or separated) and
quintiles of neighbourhood income (based on the postal
code of residence at the time of delivery).
2.2. Analysis. Extended Cox proportional hazards regression
models were used to analyse the data [67]. Time zero was
recorded as the date of birth. Duration of follow-up was
measured in weeks. Subjects were censored the week they
were identiﬁed as having asthma, died or were lost to follow-
up. Given the outcome of asthma was not considered before
156 weeks the minimum amount of follow-up time required
to be included in this analysis was therefore 156 weeks.
A Cox proportional hazards regression stratiﬁed by
antenatal steroid therapy was utilized to assess the time
dependant hazard comparing subjects that received and did
not receive steroid therapy. A kernel smoothing method was
utilized to remove the extreme variability in the time-speciﬁc
hazard estimates [68, 69].
Given that one mother may give birth to more than
one infant in the cohort an examination of robust variance
estimates was undertaken using a sandwich estimator. The
nonindependence altered the variance estimates by less than
5 percent so no consideration of this nonindependence was
given in subsequent analysis.
To quantitatively assess if the hazard ratio for the
association between exposure to antenatal corticosteroids
and the subsequent development of asthma changes with
time, an extended Cox proportional hazards regression with
time-dependant covariates was used. The eﬀect of steroid
administration through time was described by three hazard
ratios; one when time was between 156 and 260 weeks, one
when time was between 261 and 364 weeks and one when
time was greater than 364 weeks. These time periods were
selected based on an examination of the smoothed ﬁgure
derived from the stratiﬁed Cox model.
All potential confounders were examined with nested
models with the time-dependant covariates for steroid
administration. Each potential confounder’s eﬀect on the
parameter estimates for antenatal steroid therapy (early,
mid and late) was assessed by examining the percentage
diﬀerence in the parameter estimates from a model with and
without the potential confounder. Diﬀerences larger than 10
percentinanyoneoftheparameterestimateswasconsidered
evidence of confounding [70]. Potential cofounders that did
not demonstrate evidence of confounding were not retained
in the ﬁnal models.
Thus, the statistical model for the ﬁnal analysis was as
follows:
h(t,X(t)) = h0(t)exp

β1(steroid)g1(t)+β2(steroid)g2(t)
+β3(steroid)g3(t)+βx

,
(1)
where
g1(t) =

1 if 156 <t≤ 260 weeks,
0i f t<260 weeks,
g2(t) =

1 if 261 ≤ t ≤ 364 weeks,
0i f t<261 or t>364 weeks,
g3(t) =

1, if t ≥ 365 weeks,
0, if t<365 weeks,
βx =

x other covariates.
(2)
All statistical analyses were performed using SAS version
8.2.
3. Results
There were a total of 113,145 births between January 1,
1989, and December 31, 1998, in Nova Scotia. Exclusions
included 1,325 fetal, neonatal or infant deaths that occurred
before 1 year of age, 2,408 infants who were delivered from a
multiple gestation, 4,958 infants who were born to mothers
experiencingactiveasthmaduringthegestationalperiodand
a further 89 infants were excluded because they were born to
mothers experiencing endocrine abnormalities.4 Journal of Pregnancy
Table 1: Descriptive characteristics of the study sample by asthma status.
Asthma
No Yes Total
%%
Num Row Column Num Row Column Num %∗
Total 59,975 74.6 100.0 20,473 25.4 100.0 80,448 100.0
Birth year
1989 3,823 65.1 6.4 2,051 34.9 10.0 5,874 7.3
1990 5,816 66.5 9.7 2,931 33.5 14.3 8,747 10.9
1991 5,671 67.2 9.5 2,773 32.8 13.5 8,444 10.5
1992 6,020 71.7 10.0 2,374 28.3 11.6 8,394 10.4
1993 6,135 74.0 10.2 2,152 26.0 10.5 8,287 10.3
1994 6,524 75.9 10.9 2,067 24.1 10.1 8,591 10.7
1995 6,503 77.4 10.8 1,896 22.6 9.3 8,399 10.4
1996 6,793 80.7 11.3 1,629 19.3 8.0 8,422 10.5
1997 6,465 81.8 10.8 1,440 18.2 7.0 7,905 9.8
1998 6,225 84.3 10.4 1,160 15.7 5.7 7,385 9.2
Antenatal steroid exposure 773 68.1 1.3 362 31.9 1.8 1,135 1.4
Number of siblings
0 25,916 72.2 43.2 9,972 27.8 48.7 35,888 44.6
1 21,753 75.1 36.3 7,199 24.9 35.2 28,952 36.0
2 8,691 78.1 14.5 2,435 21.9 11.9 11,126 13.8
3+ 3,608 80.7 6.0 864 19.3 4.2 4,472 5.6
Preterm birth (<37 weeks) 2,534 68.1 4.2 1,189 31.9 5.8 3,723 4.6
Caesarean section 10,873 71.9 18.1 4,253 28.1 20.8 15,126 18.8
Income
Quintile 1 12,693 73.6 21.5 4,547 26.4 22.7 17,240 21.4
Quintile 2 12,619 74.3 21.4 4,359 25.7 21.7 16,978 21.1
Quintile 3 11,368 75.2 19.3 3,749 24.8 18.7 15,117 18.8
Quintile 4 12,435 74.6 21.1 4,235 25.4 21.1 16,670 20.7
Quintile 5 9,873 75.7 16.7 3,174 24.3 15.8 13,047 16.2
Surfactant administration 139 59.9 0.2 93 40.1 0.5 232 0.3
1 Minute Apgar score
0–3 1,309 70.4 2.2 550 29.6 2.7 1,859 2.3
4–6 4,375 71.9 7.3 1,712 28.1 8.4 6,087 7.6
7–10 54,070 74.9 90.5 18,137 25.1 88.9 72,207 89.8
Maternal smoking 16,421 72.6 27.4 6,211 27.4 30.3 22,632 28.1
Married/Common law 42,671 74.6 71.1 14,566 25.4 71.1 57,237 71.1
Hyaline membrane disease 672 62.3 1.1 406 37.7 2.0 1,078 1.3
Bronchopulmonary dysplasia 97 54.2 0.2 82 45.8 0.4 179 0.2
Duration: weeks (mean, SD) 512.3 155.3 287.2 116.6 455.0 176.2
Birth weight: grams (mean, SD) 3,487.4 554.7 3,444.3 592.1 3,476.5 564.7
Gestational age: weeks (mean, SD) 39.5 1.7 39.3 1.9 39.4 1.7
Maternal age: years (mean, SD) 26.7 5.3 26.4 5.2 26.6 5.3
Note:All totals do not add to grand total given missing values for some variables.
∗Percent of total cohort.
There were 104,365 infants eligible for record linkage.
Birth records for 18,627 infants could not be successfully
linked to the health care follow-up data due to errors or
missing information with the provincial unique identiﬁer.
Due to deaths, migration, and other events an additional
3,484 infants did not have 156 or more weeks of follow-
up time. A further 1,671 infants did not have either a birth
weight or gestational age recorded (which is required for
the analysis), 135 infants were greater than or less than
three standard deviations from their mean sex-speciﬁc birthJournal of Pregnancy 5
Table 2: Rates of antenatal steroid therapy administration and preterm birth by year of birth.
Total births Steroid administration
Preterm Full term Preterm birth
Num Num Rate Num Rate Num Rate
Year of birth
1989 5,874 26 109.24 18 3.19 238 40.52
1990 8,747 49 129.63 18 2.15 378 43.21
1991 8,444 58 164.31 28 3.46 353 41.80
1992 8,394 79 201.02 40 5.00 393 46.82
1993 8,287 69 195.47 36 4.54 353 42.60
1994 8,591 68 181.82 48 5.84 374 43.53
1995 8,399 78 186.16 34 4.26 419 49.89
1996 8,422 99 235.71 46 5.75 420 49.87
1997 7,905 106 261.08 60 8.00 406 51.36
1998 7,385 99 254.50 76 10.86 389 52.67
Total 80,448 731 196.35 404 5.27 3,723 46.28
Note: Rate is per 1,000 births.
weight for gestational age and therefore were excluded. This
left 80,448 infants for analysis.
Table 1 providesdescriptivestatisticsforthestudysample
by asthma status. Both a row and column percentage is
provided to assist in the interpretation of the relationships.
The asthma incidence among birth cohorts peaked in 1989
and has been on a decline since. The number of siblings,
income, marital status, mean birth weight, mean gestational
age and mean maternal age at birth are similar between
asthmatics and nonasthmatics. Infants born preterm had
an elevated incidence of asthma over the follow-up period.
As expected, children who developed asthma had higher
prevalence of caesarean section, surfactant administration,
maternal smoking, hyaline membrane disease and bron-
chopulmonary dysplasia compared to children who did not
develop asthma. The median overall follow-up time was
nearly 8.5 years (440 weeks). On average asthma developed
in this cohort at approximately 5.5 years of age (287 weeks).
Table 2 provides the rates of antenatal steroid therapy
administration and preterm birth by year of birth. The use
of antenatal steroid therapy increased 3-fold over the 10-year
time period of the study, from a rate of 7.5 in 1989 to 23.7
per 1,000 births in 1998. The preterm birth rate increased
approximately 30 percent over the same period, from a rate
of 40.5 in 1989 to 52.7 per 1,000 live births in 1998.
Figure 1providesthesmoothedadjustedhazardfunction
over time, stratiﬁed by antenatal steroid therapy. Adjust-
m e n t sw e r em a d ef o rt h ei n f a n t ’ ss e x ,g e s t a t i o n a la g ea t
birth and year of birth. Given the smoothing algorithm
used a bandwidth of 75 weeks, the tales of the curves have
not been estimated. The ﬁgure provides evidence that the
hazard for developing asthma diﬀers by antenatal steroid
therapy dependant on time. The diﬀerence is greatest in the
early period, diminishing over the middle period with little
diﬀerences noted beyond 7 years (400 weeks).
Table 3 contains the estimated adjusted hazard ratios for
the development of asthma for antenatal steroid therapy
from 3 to 5, 6 to 7 and 8, or greater years of age along
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Figure 1: Smoothed Hazard Function Estimates by Antenatal
Steroid Therapy. Note: Adjusted for gender, gestational age and year
of birth.
with the estimates for all other confounders in the model.
Adjustments were made for infant’s sex, gestational age
at birth and an indicator for perterm birth, one minute
Apgar score, administration of surfactant, infant’s birth
weight, delivery by caesarian section, maternal smoking
during the gestational period, hyaline membrane disease,
bronchopulmonary dysplasia, number of siblings and year
of birth. Unadjusted hazard ratio estimates are also provided
for the antenatal steroid exposure. The eﬀect of antenatal
steroid therapy on the development of asthma is seen to be
largerinearlychildhood(HR=1.19,95%CI:1.03,1.39)with
no eﬀect noted in mid childhood (HR=1.06, 95% CI: 0.86,
1.30) and potentially a protective eﬀect in late childhood
(HR=0.74, 95% CI: 0.54, 1.03).
When considering the more conservative deﬁnition of
asthma the prevalence of asthma dropped from 25.4%
to 18.0%. The estimated adjusted hazard ratios for the6 Journal of Pregnancy
Table 3: Association between antenatal steroid therapy exposure and childhood asthma.
Adjusted Unadjusted
HR 95% CI HR 95% CI
Antenatal steroid exposure
3–5 years 1.19 1.03–1.39 1.55 1.36–1.77
6–7 years 1.06 0.86–1.30 1.36 1.12–1.65
8+ years 0.74 0.54–1.03 0.98 0.72–1.34
Male gender 1.24 1.21–1.28 —
Preterm birth (<37 weeks) 1.03 0.95–1.12 —
Number of siblings
01 . 0 0 —
1 0.90 0.88–0.93 —
2 0.78 0.74–0.82 —
3+ 0.67 0.62–0.72 —
Bronchopulmonary Dysplasia 0.98 0.74–1.31 —
Hyaline Membrane Disease 1.14 1.01–1.30 —
Surfactant Administration 1.07 0.82–1.40 —
1 Minute Apgar Score
0–3 1.00 —
4–6 0.95 0.86–1.05 —
7–10 0.87 0.79–0.95 —
Caesarean section 1.11 1.07–1.15 —
Maternal smoking 1.12 1.09–1.16 —
Birth weight (per 500 grams) 1.00 0.98–1.01 —
Gestational age (weeks) 0.97 0.96–0.98 —
Birth year
1989 1.47 1.37–1.59
1990 1.45 1.35–1.56 —
1991 1.49 1.39–1.60 —
1992 1.28 1.19–1.37 —
1993 1.21 1.12–1.30 —
1994 1.14 1.06–1.23 —
1995 1.12 1.04–1.20 —
1996 0.99 0.92–1.07 —
1997 1.02 0.95–1.11 —
1998 1.00 —
Note: Adjustment for all other confounders in table.
development of asthma for antenatal steroid therapy from 3
to 5, 6 to 7 and 8 or greater years of age were HR=1.37 (95%
CI: 1.15, 1.62), HR=1.17 (95% CI: 0.93, 1.49) and HR=0.92
(95% CI: 0.67, 1.26), respectively. Adjustments were made
for the same confounders as in the main model.
4. Discussion
Antenatal steroid therapy appears to be an independent
risk factor for the development of childhood asthma after
controlling for confounding. The risk appears to be time-
dependent with the highest risk early in childhood and
diminishing as the child ages. The reasons for this increase
risk are not obvious but many animal studies have estab-
lished latent eﬀects of corticosteroid exposure in utero.
Although a mechanistic link between antenatal corticos-
teroid therapy and the onset of asthma in childhood has not
been fully established [71], wide ranging eﬀects of corticos-
teroid therapy have been demonstrated. The alteration in
brain chemistry and hypothalamic-pituitary-adrenal (HPA)
axis, the shift in immune function and other wide-ranging
latent eﬀects such as changes in kidney development and
subsequent hypertension all provide biological plausibility
for a link to childhood asthma.
Time-dependentcomplicationsassociatedwithantenatal
corticosteroid therapy have been demonstrated [15, 16].
Corticosteroids have been shown to aﬀect HPA development
inprimates,sheepandtoalimitedextentinhumans[17–20].Journal of Pregnancy 7
The HPA axis is important in regulating the physical growth
and organ development of the neonate [18]. The timing of
exposure to corticosteroids within a species, late in gestation,
has been shown by Matthews to be critical with regard to the
eﬀect on the HPA axis [17, 21]. Published and unpublished
work by Clifton in Australia indicates that corticosteroid
exposure not only alters the HPA axis but also inﬂuences the
Th1/Th2 ratio in favour of Th2 [72].
Strengths of this study are rooted in the large population
cohort that were assembled and followed for extended
lengths of time. The availability of potential confounders for
controlwasextensive.Controlforconfoundingbyindication
was also inherent in this study design providing considerable
methodological strength.
The retrospective nature of this study design has a
number of limitations. The reliability and validity of an
asthma diagnosis in the MSI data is unknown. Errors in
the primary reason for admission in the CIHI Hospital
Discharge Data may occur when several competing causes of
admission are present in any one individual. Errors of this
sort, with both databases, would have a conservative eﬀect
on the estimate of association generated in this study.
When considering the more conservative deﬁnition of
asthma the pattern of early childhood risk for the develop-
ment of asthma after antenatal exposure to corticosteroids
remains the same as with the main asthma deﬁnition. As
expected with this deﬁnition the risk estimate, particularly in
the early childhood period is greater. This sensitivity analysis
lends credence to the hazard ratio estimates using the main
asthma deﬁnition.
Limitationsinthemeasureofexposureexist,inthatthere
is no measure of the CS that crosses the placenta and is
biologically available to each fetus. Information that pertains
to multiple exposure to CS therapy and the actual amount
of medication administered is not recorded in the NSAPD.
With all data limitations outlined, bias would only result if
there was a systematic diﬀerence between those exposed to
CS therapy and those not exposed. There is no indication
that physician billing or hospital discharge records would be
diﬀerent based on exposure.
Given that this study is focussed on mothers and infants
from the province of Nova Scotia, Canada, any ﬁndings
from this current study would need to be replicated in
other populations to strengthen external validity. Although
no factors speciﬁcally related to the biological eﬀects of CS
therapy are postulated to diﬀer between this population
and others, other factors related to childhood asthma may
diﬀer. The trend in asthma incidence by birth year for
this population appears to be diﬀerent than that of other
populations and therefore replication of these ﬁndings in
diﬀerent populations is warranted.
Continued research into the perinatal factors in the
etiology of childhood asthma is warranted. Information
continues to surface that draws attention to the potential
longtermconsequencesofexposuresinuteroandsubsequent
diseaserisk.Cohortstudiesthatexaminethetime-dependant
eﬀects are crucial in establishing periods of disease suscep-
tibility. Although only a small, but signiﬁcant, elevated risk
for childhood asthma and antenatal steroid exposure was
demonstrated in the current study, further research into the
smallest possible dose required for the steroid to achieve
the desired post-natal eﬀect could be undertaken potentially
limiting the long term consequences such as childhood
asthma.
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